Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | ARG1 | P05089 | 2/20 | 0.48 |
| ▸ | ARG2 | P78540 | 2/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2214408 | 0.98 | SMN1; SMN2 (0.63) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL4036112 | 0.98 | SMN1; SMN2 (0.63) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL7268812 | 0.94 | SMN1; SMN2 (0.58) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL8109264 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL6946467 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL3150518 | 0.86 | SOS1 (0.55) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL4033714 | 0.86 | SIGMAR1 (0.51) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL4034621 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL4513928 | 0.83 | SMN1; SMN2 (0.65) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL4513933 | 0.83 | HRH3 (0.67) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298051-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | THE UNIVERSITY OF TOKYO (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170298051-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | THE UNIVERSITY OF TOKYO (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-3053911-A1 | ADIPONECTIN RECEPTOR-ACTIVATING COMPOUND | The University of Tokyo (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-20160214967-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | THE UNIVERSITY OF TOKYO (JP) | 2016-07-28 | — | — | US | disclosed |
| US-20160214967-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | THE UNIVERSITY OF TOKYO (JP) | 2016-07-28 | — | — | US | disclosed |
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | disclosed |
| US-20090306141-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090197914-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| US-7528156-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-05-05 | — | — | US | disclosed |
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030162772-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-28 | — | — | US | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| WO-2002066460-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
| EP-1212299-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca UK Limited (GB) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014333-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 2001-03-01 | — | — | WO | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197914-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | CCR3, CCR1, CCR4 | SMN1; SMN2 2322/4885POLB 1372/4885SIGMAR1 2123/4885 |
| US-20160214967-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | ADIPOR1, ADIPOR2, CCKAR | SMN1; SMN2 4372/4885POLB 4574/4885SIGMAR1 1649/4885 |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | SMN1; SMN2 614/4885POLB 413/4885SIGMAR1 4659/4885 |
| US-20090306141-A1 | Novel Compounds | CHRM2, CHRM1, C1R | SMN1; SMN2 1179/4885POLB 3882/4885SIGMAR1 267/4885 |
| US-20030162772-A1 | Novel compounds | RPS4X, RPS4Y1, MRPS18A | SMN1; SMN2 1658/4885POLB 3929/4885SIGMAR1 640/4885 |
| US-20170298051-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | ADIPOR1, ADIPOR2, CCKAR | SMN1; SMN2 4372/4885POLB 4574/4885SIGMAR1 1649/4885 |
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | CCR1, CCR4, CCR10 | SMN1; SMN2 3299/4885POLB 2129/4885SIGMAR1 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.